drugset
drugset / Trial / NCT00259883

Combination Of PAXIL Tablet And Benzodiazepines

NCT00259883 ↗

Phase 4 Completed 150 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study was designed to assess the efficacy and safety of combination therapy of PAXIL and benzodiazepine anxiolytics. PAXIL Tablet will be administered to patients with depression or depressive episodes who have received Benzodiazepines for at least 4 weeks, and changes in the symptoms of depression will be evaluated by use of the rate and extent of decrease in Hamilton Rating Scale for Depression (HAM-D).

Timeline

Start
2005-06
Primary completion
2006-02
Completion
2006-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Paroxetine Small molecule 20 mg —
Subject Paroxetine Small molecule 40 mg —

Indications

mental disorder